Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 15 Publications

5 Customer Reviews

  • for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

  • Determination of mutation frequencies in cells treated with chemotherapy drugs following caspase inhibition. TK6 cells were incubated with no inhibitor or 10 μM QVD then treated with the following drug doses: 300 ng/ml TRAIL, 0.7 μM cisplatin, 0.5 μM temozolomide, 3 nM doxorubicin, 0.5 nM SN38 or 0.07 nM vincristine. (a) Caspase activity was assessed by luminescent detection of Caspase-3/-7 Glo reagent after 5 h. After 24- h treatment, (b) clonogenicity assays were performed to determine the proportion of cells maintaining clonogenic competency after treatment, whereas (c) surviving cells were grown in 6TG to select for the emergence of any HPRT mutants. (d) Clonogenicity and (e) HPRT mutation assays were repeated in CASP3/7 DKO lines in the same manner. Error bars represent mean±S.E.M. from at least three independent experiments. Two-sided T-tests were used to calculate P-values.

    Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454. Vincristine sulfate purchased from Selleck.

  • Discrimination of micronuclei induced by EMS and VCR in V79-hCYP2E1-hSULT1A1 cells as CENP-B negative or positive. The cells were treated with EMS (5 mM) or VCR (5 nM) for 6 h, followed by a recovery period of 18 h. They were stained for CENP-B (green) and β-tubulin (red) by the immunofluorescence assays, as described in Section 2.5. DNA was stained with DAPI (blue). The vertical and horizontal arrows indicate CENP-B-negative and CENP-B-positive micronuclei, respectively.

    Chemosphere, 2018, 210:467-475. Vincristine sulfate purchased from Selleck.

  • c Quantification of surviving colony numbers from clonogenic assays of D283 Med cells exposed to 10, 20, or 40 μM lomustine with or without 10 nM E2 (n = 6 for each group). d Quantification of colony number from clonogenic assays of D283 Med cells exposed to 5, 10, or 20 nM vincristine with or without 10 nM E2 (n = 8 for each group). All results are expressed as mean ± SEM. Significant differences from the control group were determined by two-way ANOVA followed by Holm-Sidak’s post-test analysis and is indicated above the error bars; * p ≤ .05

    BMC Pharmacol Toxicol, 2017, 18(1):63. Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M2S4TWNmdGxiVnnhZoltcXS7IFHzd4F6 NG\K[oQxNTBwNTFOwG0> MXeyOEBp MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGDSdYMzPTZ4M{e2PS=>
HepG2-HBV1.1 MmLMRZBweHSxc3nzJGF{e2G7 NX61flJVOC1yLkWg{txO NHTlfIkzPCCq M33DOIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NVzyVGt[OjV4NkO3Olk>
HepG2.2.15 NYe3b3I1TnWwY4Tpc44hSXO|YYm= MX:wMlEh|ryP NHvT[HgzPCCq Ml35dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u M1jifFI2PjZ|N{[5
HepG2-HBV1.1 NGfROYpHfW6ldHnvckBCe3OjeR?= M4TCOFAvOSEQvF2= M1XSNlI1KGh? MY\wdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= MUiyOVY3Ozd4OR?=
HepG2-HBV1.1 NXPCd3IyTnWwY4Tpc44hSXO|YYm= MoGyNE4yKM7:TR?= NVzEfpJHPDhiaB?= MVrwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> MWWyOVY3Ozd4OR?=
HepG2-HBV1.1 M2f0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfyNE4yKM7:TR?= M4rk[lEuPSCm MmTxbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= M{TPNlI2PjZ|N{[5
HepG2-HBV1.1 NVm5V2lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DvOVAvOSEQvF2= MmLVNU02KGR? M2jHe4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= M1PwZVI2PjZ|N{[5
HepG2-HBV1.1 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjEWVAxNjFizszN M3G3XlEzNTd{IHi= NXyweGg5cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm NV3tWZdoOjV4NkO3Olk>
HepG2-HBV1.1 M2P3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlEh|ryP NHm1V28yOi15MjDo NIfJOnBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MUeyOVY3Ozd4OR?=
Raji MkLxSpVv[3Srb36gRZN{[Xl? MXKwMlXDqM7:TR?= NVu3WZVtPzJiaB?= MoLOZYJwdGm|aHXzJIF2fG:yaHHnfeKh NXWxXYN4OjV2NE[zO|c>
SK-MEL-28  MoLFSpVv[3Srb36gRZN{[Xl? M1rk[FMxKG6P MW[2JIg> NHy5e4lqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= MVyyOVMyOzBzMB?=
H157 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\TWGlEPTB;MT6wN{DDuSByLkC0JI1qfTKP NWXkXYlSOjV{NUe5NVE>
Jurkat M3rvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HkeFEuOyCwTR?= NXTjdFl1PDkEoHi= MkXpSG1UVw>? NFT5Wo9l\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MYGyOVE2PjF2Nh?=
CEM MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf3blJPOS1|IH7N NIKwO3c1QMLiaB?= NUTYU4ljTE2VTx?= MUnk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NHzRXm4zPTF3NkG0Oi=>
P12 NEP1U3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TsOFEuOyCwTR?= MV20POKhcA>? NUjDbZZxTE2VTx?= NV2wc21w\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? MWiyOVE2PjF2Nh?=
KB NFHwWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[4OHh2UUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> M4fEe|I2ODV6NUK2
KBv200 (ABCB1) NYrZW2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LYcmlEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= M{GxTlI2ODV6NUK2
SUDHL6  NFHRPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\h[oNbOeLCid88US=> NHrZZ5c1QC95MjDo M{XtV4lvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> Ml\NNlQ6PjF4MES=
SUDHL6  M1H6ZmZ2dmO2aX;uJGF{e2G7 MmLDNgKBkc7:TR?= MnzhO|IhcA>? MYDpcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C MV:yOFk3OTZyNB?=
HCT-116 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r2cWdKPTB;NTDuUS=> MWqyOFkzPzh3Nx?=
SKNBe2C M3;ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnOZZRVUUN3ME2zNk45yrF2LkCgcm0> NH\MRVAzPDl{MUmyNC=>
IGNR91 NYPQNnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\OSmlEPTB;MkSuN:KyOS55IH7N M2LXdlI1QTJzOUKw
SKNAS M3;rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPkW41KSzVyPUGuOeKyOC5{IH7N NEju[XIzPDl{MUmyNC=>
LAN1 NEHMXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG4[XhGUUN3ME2yMlPDuTBwMjDuUS=> MWCyOFkzOTl{MB?=
SHSY5Y NWTlTnZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXETWM2OD16LkNCtVAvPiCwTR?= NFX1PVkzPDl{MUmyNC=>
A549-WT NFnRSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILOUGtKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= MV:yOFg2QDh{Nx?=
A549-R MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTOUo5LUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N NUfRSlhrOjR6NUi4Nlc>
MCF-7-WT NYTmeo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyNG0xUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N NYPVTJpEOjR6NUi4Nlc>
MCF-7-R NULJ[ZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvNTWM2OD13LkWzPUDDuSByLkG0OEAhdk1? NXOxdlhTOjR6NUi4Nlc>
A549-R M4G0NWN6fG:2b4jpZ4l1gSCDc4PhfS=> NXP5bG1LUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= M2fPUVI1QDV6OEK3
MCF-7-R NVvtUGt2S3m2b4TvfIlkcXS7IFHzd4F6 MXjJR|UxRTVwNUO5JOKyKDBwMUS0JI5O MUSyOFg2QDh{Nx?=
SW620 NFvhS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdwOECgxtEhOC5yODDuUS=> NH;4RmUzPDd{NkezPS=>
SW620/AD300 NITRTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjUNXdKSzVyPUmwPU43OCEEsTC4MlkyKG6P NY\6WpJbOjR5Mk[3N|k>
HEK293/pcDNA3.1 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXOeHFKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? M33YZ|I1PzJ4N{O5
HEK293/ABCC1 M2HaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF7LkK5JOKyKDJwMEigcm0> M1m4R|I1PzJ4N{O5
TCC M1;5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLUS3EzPCCq NX3I[YI1UUN3ME23NEBvVQ>? MlLWNlQ4OTZ7NES=
TCC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jCTFQ5KGh? MX3JR|UxRTVyIH7N NVj1TY1ZOjR5MU[5OFQ>
HepG2/ADM MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? NH7uSoczPDdyNEW1Oi=>
HepG2 M13FeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7wWW5[UUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= M1G1e|I1PzB2NUW2
MCF-7/ADR M3HhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33zdWlEPTB;ND60PFI3yrFyLkKwO|Ah|ryP MXyyOFcxPDV3Nh?=
MCF-7 M2LW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEG1PeKyOC5yME[yJO69VQ>? MlnoNlQ4ODR3NU[=
A-172  Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;PT2l[OC5zwrFOwG0> MV:yOE84OiCq MlHmbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NVHw[492OjR3M{CyN|U>
U-251MG NHvuPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nMcFAvOcLizszN NUTrV2N7OjRxN{KgbC=> NWfpU|RncW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MmLCNlQ2OzB{M{W=
DLD-1 NV;rXo04TnWwY4Tpc44hSXO|YYm= NIjxNlQyODBibl2= M1HhWFQ5KGh? NEHPTIRxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? MnnoNlQ1ODN2NUO=
CCD18Co NXfHRXp1TnWwY4Tpc44hSXO|YYm= NEmzSGsyODBibl2= MoTGOFghcA>? NVyyWVdReHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi M2LaSlI1PDB|NEWz
DLD-1 NHXC[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVExODBibl2= NXH5e2Q2PDhiaB?= M4roNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXHERotpOjR2MEO0OVM>
CCD18Co M172OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWwMVExODBibl2= M3fZZ|Q5KGh? MnHYbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIXEOGQzPDRyM{S1Ny=>
HepG2 NHjXUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3e|I1KGh? MnLPTWM2OD13Mj615qCK|ryP NXzBWFFGOjR|NEG2PFg>
HEK293/pcDNA3.1 NXLZOmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD0TWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? M2\kUFI1Ojh2N{iz
HEK293/MRP1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEW1xtExNjBzMkCg{txO MVOyOFI5PDd6Mx?=
Ramos M3n1U2Fxd3C2b4Ppd{BCe3OjeR?= M{PPWVLjiIoQvF2= M4nzdFQ5KGh? M3LHWIlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? M3i0fFI1OjV4NEmx
NCI-H1299/pcDNA3 M4q4Z2NmdGxiVnnhZoltcXS7IFHzd4F6 Mm\MNE0zOCCwTR?= MonRPVYhcA>? M3\5NolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NE\3fFgzPDF5N{CxNi=>
H1299/ICAM-3 NX64[oJtS2WubDDWbYFjcWyrdImgRZN{[Xl? M1LMbVAuOjBibl2= NELmcYs6PiCq NHnhZ2ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NIH6b2YzPDF5N{CxNi=>
NCI-H1299/pcDNA3 MkDKSpVv[3Srb36gRZN{[Xl? MnThNU82NzFyL{KwxsBvVQ>? MUe5OkBp NXrNb3JkcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M1H6OFI1OTd5MEGy
H1299/ICAM-3 NIny[5ZHfW6ldHnvckBCe3OjeR?= NITWeocyNzVxMUCvNlDDqG6P MkLoPVYhcA>? NVrBNlU{cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M1nLd|I1OTd5MEGy
W1 NFnNNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe1TWM2OD1yLkCwN|Ih|ryP M2T3PFI1OTRyMUe2
W1VR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEW2JO69VQ>? MmjNNlQyPDBzN{[=
K562 M1fhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HHW2lEPTB;MD6wN|IhyrFiMD6wNFEhKM7:TR?= MmrlNlQyOzV7M{e=
K562/ADR MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrPTWM2OD1|LkK2NUDDuSByLkSxNkDPxE1? MV6yOFE{PTl|Nx?=
K562 NH20UZlCeG:ydH;zbZMhSXO|YYm= NF[ycFkxNjNizszN M3u3c|I1KGh? M1zmSIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NVzBSpJ3OjRzM{W5N|c>
K562/ADR MYnBdI9xfG:|aYOgRZN{[Xl? M4PqZVMh|ryP MV:yOEBp NYT6OZlGcW6mdXPld{BieG:ydH;zbZM> NES5fpQzPDF|NUmzOy=>
A549 NXrFU|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUCgxtEhOC5yMzFOwG0> NW\zW3dUOjN7N{GwO|U>
K562 NVKydIh6S2WubDDWbYFjcWyrdImgRZN{[Xl? MknLN{44PeLCk{[wxsBvVQ>? M2XvR|czyqCqwrC= MmLHbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHjoR|IzOzh5N{KyNy=>
lucena M4TlbmNmdGxiVnnhZoltcXS7IFHzd4F6 NXXQTYtROy55NfMAl|YxyqCwTR?= MU[3NuKhcMLi M4rBXY5wKGWoZnXjeC=> MoLxNlM5Pzd{MkO=
FEPS NGL3fnhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3q5bVMvPzYkgKO2NOKhdk1? Mof2O|LDqGkEoB?= M1\1WI5wKGWoZnXjeC=> Mn\NNlM5Pzd{MkO=
A2780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXs[oRpUUN3ME2zMlUhdU1? M3nhTlI{QDJ7MkCz
ACHN NVTyV4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjhRmdKSzVyPECuNUBuVQ>? M1r5dVI{QDJ7MkCz
U-937 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;3bmxKSzVyPEO0JI5O M{nNcFI{QDJ7MkCz
Jurkat NW\HWFgxSXCxcITvd4l{KEG|c3H5 M3PzT|XDqM7:Zz;tcOKh MkW0NlQhcA>? MWjpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NVrMcno{OjN6MUC0NFk>
Jurkat M1HNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRfGs1PcLizsznM41tyqB? M1HtfVI1KGh? M1vyXoFzemW|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG|ZR?= MWSyN|gyODRyOR?=
Hep-2 NG\KenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvPS3JmUUN3ME2wMlA1yrFyLkCxJO69VQ>? NXziOGZDOjN5OEC0NlQ>
Hep-2/v NWLme2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\4TWM2OD1zLklCtVAvOjBizszN NVKwRpZCOjN5OEC0NlQ>
SGC-7901 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvGclkxNTFyIN88[{9udA>? NEnKfXYzPC92OD:3NkBp M3viWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NF[3R|UzOzd2M{W3Ni=>
SGC-7901/VCR NXjseJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGwNE0yOCEQvHevcYw> MXiyOE81QC95MjDo M1S3S4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NWTDOJROOjN5NEO1O|I>
SGC-7901 M{DjVmFxd3C2b4Ppd{BCe3OjeR?= MoXEbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MkLVNlM4PDN3N{K=
SGC-7901/VCR NF;0fI5CeG:ydH;zbZMhSXO|YYm= NH3W[mxqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NWC4Z4xMOjN5NEO1O|I>
KB-3-1 NXH3[W43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq0[mhlUUN3ME2xMlY3KMLzIECuNVYzKM7:TR?= M1LQSFI{Pjd|NES1
KB-C2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7uSYVKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN MUOyN|Y4OzR2NR?=
KB-3-1 NYWyRlYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr6cGRKSzVyPUGuNlYhyrFiMD6wNlch|ryP MkjuNlM3PzN2NEW=
KB-V1 NXPad2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\IWGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP M1vYUFI{Pjd|NES1
HEK293/pcDNA3.1 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3GTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NWXDR2l3OjN4N{O0OFU>
HEK293/ABCB1 M{P5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= MV6yN|Y4OzR2NR?=
A549/EGFP  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OxO|AvODFvMUCwNEDPxE1? NUSzeYFoUUN3ME24Ok44KMLzIEK5MlEh|ryP M1\pN|I{PjN2Mkiy
A549/Slug MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWwMlAyNTFyMECg{txO NFuwSJdKSzVyPUmuO{DDuSB|LkGg{txO MoLUNlM3OzR{OEK=
JFCR39  M2LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nRXlEhyrWP M4XoRlI1KGh? NH33OVFFVVOR NGnzZ4Nu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| NVKy[pdUOjN3OUiyO|Y>
A549 MYTGeY5kfGmxbjDBd5NigQ>? NUPEUJJMOTByIH7N NX3sOI5uOTZiaB?= MYPEUXNQ MoWwcIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? MorUNlM2QTh{N{[=
SGC7901 M3HFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG5b3FKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t NYe5VIVoOjN3NkS0PFI>
SGC7901/LV-NC Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;zWWlEPTB;MT63O-KBkcLz4pEJNE4yPiEQvHevcYw> M330fFI{PTZ2NEiy
SGC7901/LV-SGO1 NVvpPVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpNYJKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t NGD6dpQzOzV4NES4Ni=>
SGC7901/VCR NGrQNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hUmlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t NX3pbod2OjN3NkS0PFI>
SGC7901/VCR-NC NH72OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=> M4i1N|I{PTZ2NEiy
SGC7901/VCR-si-SGO1 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS5TWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> M3z6TVI{PTZ2NEiy
SGC7901/ADR M2XDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrSd2VKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t MXmyN|U3PDR6Mh?=
SGC7901/ADR-NC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=> MVmyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwNEdihKnDueLCiUCuNlkh|rypL33s MnLQNlM2PjR2OEK=
SH-SY5Y  Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrFNE4xODFvMUCg{txO NXvsdnZ3OjRiaB?= MlTnTWM2OD1yLkGxN:KyOC5yMUKg{txO NHe0W20zOzF{OUC2OS=>
SH-SY5Y  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;xUFAvODBzLUGwJO69VQ>? NH63ZmE1QCCq MkL4TWM2OD1yLkC3POKyOC5yMEmg{txO M4SzdlI{OTJ7ME[1
SH-SY5Y  NYXQfW43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKwMlAxOS1zMDFOwG0> NVfIVHNSPzJiaB?= NFvCPGFKSzVyPUCuNFUyyrFyLkCwPEDPxE1? MXOyN|EzQTB4NR?=
SH-SY5Y NIriWoRCeG:ydH;zbZMhSXO|YYm= NXzjcnBVOC5zIN88US=> NF[wbIsxNTJ2IHi= NF;FdXBqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> NH;SSJYzOzF{OUC2OS=>
SH-SY5Y MYHBdI9xfG:|aYOgRZN{[Xl? MXOwMlEh|ryP NFjZOWQxNTJ2IHi= MmH0bY5lfWOnczDtbZRwfGmlIHHydoV{fMLi MY[yN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03871257 Not yet recruiting Low Grade Glioma|Neurofibromatosis Type 1|Visual Pathway Glioma National Cancer Institute (NCI) May 3 2019 Phase 3
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID